ProPhase Labs (PRPH) Competitors $0.33 -0.01 (-1.88%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.33 +0.00 (+1.28%) As of 08/22/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. IFRX, IMA, ELYM, VRCA, ABVC, DTIL, PDSB, ICCC, ANVS, and ATNMShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include InflaRx (IFRX), ImageneBio (IMA), Eliem Therapeutics (ELYM), Verrica Pharmaceuticals (VRCA), ABVC BioPharma (ABVC), Precision BioSciences (DTIL), PDS Biotechnology (PDSB), ImmuCell (ICCC), Annovis Bio (ANVS), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Its Competitors InflaRx ImageneBio Eliem Therapeutics Verrica Pharmaceuticals ABVC BioPharma Precision BioSciences PDS Biotechnology ImmuCell Annovis Bio Actinium Pharmaceuticals ProPhase Labs (NASDAQ:PRPH) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Which has more volatility & risk, PRPH or IFRX? ProPhase Labs has a beta of -0.48, indicating that its stock price is 148% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Do insiders & institutionals have more ownership in PRPH or IFRX? 9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer PRPH or IFRX? InflaRx has a consensus price target of $6.60, suggesting a potential upside of 622.50%. Given InflaRx's stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRPH or IFRX more profitable? InflaRx's return on equity of -71.76% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase LabsN/A -262.42% -76.48% InflaRx N/A -71.76%-57.68% Which has stronger earnings and valuation, PRPH or IFRX? InflaRx has lower revenue, but higher earnings than ProPhase Labs. InflaRx is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$5.59M2.44-$53.36M-$1.26-0.26InflaRx$180K340.68-$49.85M-$0.80-1.14 Does the media prefer PRPH or IFRX? In the previous week, ProPhase Labs had 1 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for ProPhase Labs and 2 mentions for InflaRx. ProPhase Labs' average media sentiment score of 0.57 beat InflaRx's score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryInflaRx beats ProPhase Labs on 11 of the 15 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.66M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-0.2622.9031.3626.05Price / Sales2.44516.56387.8788.42Price / CashN/A179.1038.0259.36Price / Book1.175.939.536.60Net Income-$53.36M$31.83M$3.26B$265.65M7 Day Performance-5.87%1.89%2.14%2.00%1 Month Performance-21.99%1.62%3.22%0.46%1 Year Performance-87.78%9.25%30.18%18.88% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs1.2463 of 5 stars$0.33-1.9%N/A-87.8%$13.66M$5.59M-0.26130IFRXInflaRx2.6799 of 5 stars$0.91+5.7%$6.60+623.4%-42.2%$57.93M$180K-1.1460News CoverageIMAImageneBio2.5119 of 5 stars$14.70+3.5%$35.50+141.5%-31.1%$57.08M$9.16M-1.9170ELYMEliem TherapeuticsN/A$1.90+10.5%N/A-60.3%$56.53MN/A-3.589News CoveragePositive NewsHigh Trading VolumeVRCAVerrica Pharmaceuticals4.5919 of 5 stars$6.16+3.4%$80.00+1,198.7%-80.6%$56.30M$7.57M-0.7440News CoveragePositive NewsShort Interest ↓ABVCABVC BioPharma0.5186 of 5 stars$3.13-5.2%N/A+348.9%$56.04M$510K-18.4130DTILPrecision BioSciences4.068 of 5 stars$4.95+5.1%$47.00+849.5%-48.8%$55.52M$68.70M-0.56200Positive NewsPDSBPDS Biotechnology2.0273 of 5 stars$1.24+4.2%$9.00+625.8%-64.5%$55.49MN/A-1.3520Positive NewsGap UpICCCImmuCell0.6274 of 5 stars$6.11+0.2%N/A+65.5%$55.15M$26.49M32.1670News CoverageShort Interest ↓ANVSAnnovis Bio2.5291 of 5 stars$2.70-1.6%$18.00+567.9%-75.4%$53.39MN/A-1.323ATNMActinium Pharmaceuticals2.4978 of 5 stars$1.71+1.2%$4.50+163.2%-13.2%$53.35MN/A-1.2330Short Interest ↓ Related Companies and Tools Related Companies IFRX Competitors IMA Competitors ELYM Competitors VRCA Competitors ABVC Competitors DTIL Competitors PDSB Competitors ICCC Competitors ANVS Competitors ATNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's Big Prediction for 2025Elon Musk just made a bold prediction about 2025—and it could upend the entire tech sector. If he’s right, ...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access